**Dear editor,**

Neuroendocrine carcinoma of the breast (NECB) accounts for approximately 0.3%--0.5% of all breast cancers \[[@CR1], [@CR2]\]. Due to the rarity of NECB, current understanding of this disease in China is limited to case reports and small case series, and large data analysis is still lacking. Therefore, we conducted the most comprehensive literature search to date, aiming to analyze the clinicopathologic characteristics as well as treatment and outcome of NECB in the Chinese population.

In the present study, we reported seven NECB cases diagnosed between 1990 and 2015 at the National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Additionally, we performed a literature search of the Wanfang and Weipu databases (using the following key words: breast, neuroendocrine, tumor/carcinoma/neoplasm/cancer, primary tumor/carcinoma/neoplasm/cancer, and breast tumor/carcinoma/neoplasm/cancer). Articles published between 2003 and 2015 were collected and reviewed (Table [1](#Tab1){ref-type="table"}). NECB case reports published in non-Chinese journals were not included in this study. The diagnosis was confirmed if (a) more than 50% of the tissue specimens exhibited neuroendocrine markers, and (b) ductal carcinoma in situ was identified and/or imaging examinations and extramammary sites were excluded. Descriptive statistics were calculated for epidemiologic, clinical, and pathologic features, for treatment, and for follow-up.Table 1Summary of published articles about neuroendocrine carcinoma of the breast included in this studyYearAuthorNumber of casesPublication information2005Zhang et al.5Zhongguo Zhongliu Linchuang 2005, 32 (13)2008Zhong et al.3Zhongguo Xiandai Yiyao Zazhi 2008, 10 (7)2008Zhou et al.7Lingnan Xiandai Linchuang Waike 2008, 8 (6)2008Cui et al.3Zhongguo Shiyong Waike Zazhi 2008, 28 (7)2009Lv et al.1Guoji Waikexue Zazhi 2009, 36 (7)2009Ren et al.1Zhongguo Aizheng Zazhi 2009, 19 (5)2009Guan et al.1Zhenduan Binglixue Zazhi 2009, 16 (6)2010Zhang et al.1Zhonghua Putongwaike Zazhi 2010, 25 (12)2010Shi et al.1Anmoyukangfu Yixue 2010, 01 (7)2010Wang et al.1Zhonghua Ruxianbing Zazhi 2010, 04 (1)2010Zhang et al.1Hanshao Jibing Zazhi 2010, 17 (5)2010Shen et al.1Zhonghua Putongwaike Zazhi 2010, 25 (10)2010Geng et al.3Dalian Yikedaxue Xuebao 2010, 32 (4)2010Jia et al.6Guangdong Yixue 2010, 31 (17)2011Zeng et al.3Linchuang Yu Shiyanbinglixue Zazhi 2011, 27 (6)2011Kuang et al.2Shiyong Yixue Zazhi 2011, 27 (7)2011Gao et al.16Zhonghua Binglixue Zazhi 2011, 40 (9)2012Li et al.1Aizhengjinzhan 2012, 10 (3)2012Zhang et al.4Hainan Yixue 2012, 23 (15)2012Zhang et al.32Zhongguo Zhongliu Linchuang 2012, 39 (1)2013Zhang et al.1Zhongwai Jiankang Wenzhai 2013, 10 (4)2013Gu et al.3Bengbuyixueyuan Xuebao 2013, 38 (2)2013Pan et al.8Zhongliu 2013, 33 (2)2014Zhong et al.1Zhonghua Laonianxue Zazhi 2014, 34 (16)2014Hou et al.2ZhongliuJichu Yu Linchuang 2014, 27 (3)2014Yu et al.4Linchuang ChaoshengYixue Zazhi 2014, (8)2015Huang et al.7ZhongliuYanjiu Yu Linchuang 2015, 27 (7)*NECB* neuroendocrine carcinoma of the breast

The main clinicopathologic features of the seven cases diagnosed at our hospital are summarized in Table [2](#Tab2){ref-type="table"}. There were six female patients and one male patient. The median age was 49 years (range, 33--78 years). All patients presented with breast lump, and one patient developed skin ulceration. Five of seven patients had the well-differentiated subtype of disease, and two patients had poorly-differentiated disease. Five patients had early-stage disease of luminal subtype. Six patients received chemotherapy and surgery, whereas one patient received chemotherapy alone. Patients with positive estrogen receptors (ERs) received endocrine therapy. The follow-up time ranged from 31 to 59 months. Five patients were alive without tumor at the last follow-up, one died of other causes, and one was lost to follow-up.Table 2Clinicopathologic features of seven patients with neuroendocrine carcinoma of the breastNo.Age (years)SexSymptomHistologyTNM stageIntrinsic subtypeTreatmentFollow-up outcome149FBreast lumpWell-differentiatedT2N0M0, IIAER3+PR2+HER2−Surgery, chemotherapy, and endocrine therapyAlive without tumor278FBreast lumpWell-differentiatedT1N0M0, IAER3+PR3+HER2−Surgery, chemotherapy, and endocrine therapyDied of other causes349FBreast lumpPoorly-differentiatedT2N0M0, IIAER3+PR+HER2−Surgery, chemotherapy, and endocrine therapyAlive without tumor458FBreast lumpWell-differentiatedT2N1M0, IIBER2+PR2+HER2−Surgery, chemotherapy, and endocrine therapyAlive without tumor543FBreast lump and skin ulcerationWell-differentiatedT3N2M0, IIIAER−PR−HER2−Surgery and chemotherapyAlive without tumor660MBreast lumpPoorly-differentiatedT4N0M1, IVER−PR−HER2−ChemotherapyLost to follow-up733FBreast lumpWell-differentiatedT2N1M0, IIBER3+PR2+HER2−Surgery, chemotherapy, and endocrine therapyAlive without tumorThese patients were diagnosed and treated at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China*F* female, *M* male, *ER* estrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2

Our literature search yielded 126 cases of NECB, including our own. We analyzed the clinicopathologic features of 126 NECB cases in China (Table [3](#Tab3){ref-type="table"}). The patients' average age was 53.2 years; there were seven male patients (5.6%) and 119 female patients (94.4%). Almost all patients (124/126, 98.4%) presented with a breast lump; six patients (4.8%) had bloody nipple discharge. No unique appearance of NECB was identified on 85 patients who underwent ultrasound examination or 66 patients who underwent mammography examination. Most patients (100/126, 79.4%) underwent mastectomy. A small percentage of patients (18/126, 14.3%) underwent breast-conserving surgery. Seven patients (5.5%) underwent breast surgery; however, the exact type of surgical procedures was not provided in the corresponding reports. One patient (0.8%) received chemotherapy alone. Overall, 55 patients received adjuvant chemotherapy; of these, 53 were initially treated with regimens for infiltrative ductal carcinoma (IDC) of the breast, including 51 receiving anthracycline- and taxane-based regimens and two receiving etoposide- and cisplatin-based regimens, and two were initially treated with the commonly used regimens for small cell carcinoma (Table [4](#Tab4){ref-type="table"}).Table 3Clinicopathologic features of 126 patients with neuroendocrine carcinoma of the breast in ChinaCharacteristicNo. of cases (%)Age (years) \<5026 (20.6) 50--5919 (15.1) 60--6911 (8.7) 70--797 (5.6) Data unstratified63 (50.0)Gender Female119 (94.4) Male7 (5.6)Symptom Breast lump124 (98.4) Bloody nipple discharge6 (4.8) Nipple erosion1 (0.8) Dimple sign1 (0.8) Skin ulceration1 (0.8)Diagnostic examination Biopsy before surgery25 (19.8) Breast ultrasound85 (67.5) Mammography66 (52.4) Breast MRI1 (0.8) Chest X-ray39 (31.0)Whole body check Abdominal ultrasound60 (47.6) Abdominal CT1 (0.8) Chest CT1 (0.8) Pelvic ultrasound7 (5.6) PET/CT1 (0.8)Histology Well-differentiated (non-small cell)52 (41.3) Poorly-differentiated (small cell)26 (20.6) NM48 (38.1)T category T129 (23.0) T239 (31.0) T324 (19.0) T48 (6.3) NM26 (20.6)N category N049 (38.9) N112 (9.5) N26 (4.8) N31 (0.8) NM58 (46.0)M category M0122 (96.8) M14 (3.2)TNM stage I30 (23.8) II60 (47.6) III14 (11.1) IV4 (3.2) NM18 (14.3)Estrogen receptor status Positive102 (81.0) Negative23 (18.2) NM1 (0.8)Progesterone receptor status Positive91 (72.2) Negative34 (27.0) NM1 (0.8)HER2 status Overexpressed19 (15.1) Not overexpressed104 (82.5) NM3 (2.4)*MRI* magnetic resonance imaging, *CT* computed tomography, *PET* positron emission tomography, *HER* human epidermal growth factor receptor, *NM* not mentioned Table 4Treatment and follow-up of 126 patients with neuroendocrine carcinoma of the breast in ChinaTreatment and follow-upNo. of cases (%)Surgery Mastectomy100 (79.4) Breast-conserving surgery18 (14.3) Other breast surgery7 (5.5) No surgery (chemotherapy alone)1 (0.8) Axillary lymph node dissection104 (82.5)Neoadjuvant therapy Received4 (3.2) None122 (96.8)Adjuvant therapy Chemotherapy55 (43.7)  Infiltrative ductal carcinoma of the breast regimen53 (42.1)  Small cell carcinoma regimen2 (1.6) Radiotherapy22 (17.5) Endocrine therapy80 (63.5)  Tamoxifen71 (56.3)  Aromatase inhibitors4 (3.2)  Tamoxifen followed by aromatase inhibitors1 (0.8)  Regimen not mentioned4 (3.2)Follow-up Alive without tumor101 (80.2) Alive with tumor9 (7.1) Died of disease7 (5.6) Died of other causes1 (0.8) Lost to follow-up8 (6.3)

According to the 2012 World Health Organization (WHO) classification, 52 cases were well-differentiated, and 26 were poorly-differentiated, the remaining 48 had no information of pathology. The percentages of patients with different stage breast cancer were as follows: stage I, 23.8% (30 of 126); stage II, 47.6% (60 of 126); stage III, 11.1% (14 of 126); and stage IV, 3.2% (4 of 126); the remaining 18 had no information about pathology. ER and progesterone receptor were present in 102 (81.0%) and 91 (72.2%) patients, respectively; and human epidermal growth factor receptor 2 (HER2) protein was overexpressed in 19 (15.1%) patients.

All cases were positive for at least one of the neuroendocrine markers (chromogranin A \[CgA\], synaptophysin \[Syn\], and neuron-specific enolase \[NSE\]) in more than 50% of tumor cells. Table [3](#Tab3){ref-type="table"} summarizes the clinicopathologic features of the 126 cases.

The follow-up time ranged from 4 to 144 months. Disease recurrence was found in 13 cases, including 4 small cell type (poorly-differentiated) cases and 9 non-small cell type (well-differentiated) cases. Seven patients died of NECB, of which four had small cell type disease and three had non-small cell type disease. The treatment and follow-up of the 126 cases are shown in Table [4](#Tab4){ref-type="table"}.

For NECB patients in China, we determined an average age of 53.2 years, which seems to be older than the onset of IDC \[[@CR3]\]. Six patients in our study presented with bloody nipple discharge. Kawasaki et al. \[[@CR4]\] examined the pathology of 89 patients who came to the hospital for a thorough examination of symptomatic bloody nipple discharge and found that 24 (27.0%) of them had neuroendocrine carcinomas. NECB may account for an important share of breast conditions associated with bloody nipple discharge. In previous reports, NECB showed no difference when compared with IDC based on imaging \[[@CR5], [@CR6]\], which was confirmed in the present study. In addition, in our study, most NECB cases showed positive ER expression, which supported the results of recent studies on gene expression profiling \[[@CR7]\], suggesting that NECB belongs to the luminal type.

Currently, there is no standard therapy for NECB. Most treatments of NECB reported in the literature and in the present study are similar to the treatment of ductal-type carcinoma, with surgery as the first-line therapy, followed by anthracycline- and taxane-based chemotherapy and endocrine therapy \[[@CR1], [@CR8]\]. However, whether NECB patients can benefit from chemotherapy is unknown. Current data provide little evidence to support the use of regimens for either small cell or non-small cell carcinoma.

Conflicting results of the prognosis of patients with NECB have been reported \[[@CR8]--[@CR10]\]. Among 126 Chinese cases included in the present study, nine of 18 patients (50.0%) with the small cell carcinoma were alive without tumor relapse, whereas the percentage was 85.0% (51/60) for those with non-small cell carcinoma. Overall, 57.1% (4/7) of patients who died of NECB had small cell breast cancer.

In summary, since NECB was first listed by the WHO in 2003 as a separate unique category, many NECB cases remain to be elucidated about their etiology and treatment. In this study, we found that the onset age of NECB patients in China seems to be older than that of IDC patients. Bloody nipple discharge may indicate the existence of NECB. Most NECB patients have the luminal subtype disease. Surgery is used as the first-line therapy, and the role of chemotherapy is still unknown. The small cell subtype may be associated with more frequent relapse and a higher mortality compared with the non-small cell subtype.
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